CL2021001817A1 - Formas cristalinas de (s)-2-(7-ciano-1h-bencimidazol-1 il)-n-{1-[4-(1- ciano-1-metiletil)fenil]etil}acetamida - Google Patents

Formas cristalinas de (s)-2-(7-ciano-1h-bencimidazol-1 il)-n-{1-[4-(1- ciano-1-metiletil)fenil]etil}acetamida

Info

Publication number
CL2021001817A1
CL2021001817A1 CL2021001817A CL2021001817A CL2021001817A1 CL 2021001817 A1 CL2021001817 A1 CL 2021001817A1 CL 2021001817 A CL2021001817 A CL 2021001817A CL 2021001817 A CL2021001817 A CL 2021001817A CL 2021001817 A1 CL2021001817 A1 CL 2021001817A1
Authority
CL
Chile
Prior art keywords
cyano
crystal forms
benzimidazol
methylethyl
acetamide
Prior art date
Application number
CL2021001817A
Other languages
English (en)
Inventor
Jilong Jiang
Alan Tse
Original Assignee
Neomed Inst Institut Neomed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neomed Inst Institut Neomed filed Critical Neomed Inst Institut Neomed
Publication of CL2021001817A1 publication Critical patent/CL2021001817A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan formas cristalinas de un compuesto de fórmula I. La Forma A cristalina se encuentra entre las formas cristalinas identificadas. La Forma A tiene un patrón de difracción de rayos X de polvo (XRPD) con picos característicos expresados en grados 2O (±0,2° 2O) a 3,07, 5,96, 11,89 y 17,85, y un termograma de calorimetría diferencial de barrido (DSC) que exhibe una endoterma que tiene una temperatura máxima de aproximadamente 168,9 °C. La Forma A cristalina es útil como una composición farmacéutica y puede usarse como un antagonista de VR1. Puede usarse en el tratamiento de trastornos de dolor nociceptivo
CL2021001817A 2019-01-08 2021-07-07 Formas cristalinas de (s)-2-(7-ciano-1h-bencimidazol-1 il)-n-{1-[4-(1- ciano-1-metiletil)fenil]etil}acetamida CL2021001817A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962789740P 2019-01-08 2019-01-08

Publications (1)

Publication Number Publication Date
CL2021001817A1 true CL2021001817A1 (es) 2022-01-28

Family

ID=71521854

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001817A CL2021001817A1 (es) 2019-01-08 2021-07-07 Formas cristalinas de (s)-2-(7-ciano-1h-bencimidazol-1 il)-n-{1-[4-(1- ciano-1-metiletil)fenil]etil}acetamida

Country Status (11)

Country Link
US (1) US20220089550A1 (es)
EP (1) EP3908574A4 (es)
JP (1) JP2022516362A (es)
KR (1) KR20210148081A (es)
CN (1) CN113631544A (es)
AU (1) AU2020207426A1 (es)
BR (1) BR112021013437A2 (es)
CA (1) CA3125655A1 (es)
CL (1) CL2021001817A1 (es)
MX (1) MX2021008251A (es)
WO (1) WO2020142842A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
UY30048A1 (es) * 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
TWI433839B (zh) * 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290

Also Published As

Publication number Publication date
EP3908574A1 (en) 2021-11-17
CN113631544A (zh) 2021-11-09
JP2022516362A (ja) 2022-02-25
CA3125655A1 (en) 2020-07-16
BR112021013437A2 (pt) 2021-10-19
AU2020207426A1 (en) 2021-08-26
MX2021008251A (es) 2021-10-13
KR20210148081A (ko) 2021-12-07
US20220089550A1 (en) 2022-03-24
EP3908574A4 (en) 2022-10-26
WO2020142842A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
PE20141050A1 (es) Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
ATE432926T1 (de) Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
AR106612A1 (es) Sales, formas cristalinas y composiciones farmacéuticas de 4-[2-(4-amino-piperidin-1-il)-5-(3-fluoro-4-metoxi-fenil)-1-metil-6-oxo-1,6-dihidro-pirimidin-4-il]-2-fluorobenzonitrilo como inhibidor de demetilasa 1 específica de lisina
CO6410293A2 (es) Nueva formula cristalina vi de la agomelatina preparación y uso de la misma
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
PE20191108A1 (es) Inhibidores selectivos de jak1
AR070560A1 (es) Formas cristalinas de acido 4-(4-(2-adamantilcarbamoil) -5-ter-butil-pirazol-1-il) benzoico 471
ECSP109900A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
IN2012DN03337A (es)
GEP201606545B (en) 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections
PE20211756A1 (es) FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß
MX2023007446A (es) Compuesto heterociclico aromatico, composicion farmaceutica y uso de estos.
ATE331711T1 (de) Entzündungshemmende 3-arylthio-3- thiazolylalkylamine